BioLineRx Ltd (NASDAQ:BLRX) stock is trading lower on Tuesday, following the announcement of new data regarding their GLIX1 treatment, which demonstrates a potent anti-tumor effect in glioblastoma.
GLIX1 Demonstrates Tumor Growth Inhibition
BioLineRx, a commercial-stage biopharmaceutical company focused on oncology, and Hemispherian revealed new preclinical data showing GLIX1’s strong anti-tumor activity, even in a temozolomide (commonly used chemotherapy)-resistant model.
In the three orthotopic cell-derived xenograft (CDX) studies, significant tumor growth inhibition and survival benefit were observed following treatment with GLIX1 across all doses tested, with greater benefit at higher dose levels.
Something went wrong.
